Body surface area‐based vs concentration‐based perioperative intraperitoneal chemotherapy after optimal cytoreductive surgery in colorectal peritoneal surface malignancy treatment: COBOX trial
- 5 March 2019
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 119 (7) , 999-1010
Abstract
Background and Objectives: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal perioperative chemotherapy (HIPEC) are the standard of care for patients diagnosed with colorectal peritoneal surface malignancy (PSM). Despite a clearly defined standardization of CRS, a large variety of HIPEC modalities are still used in clinical practice.Methods: Body surface area (BSA)‐ and concentration‐based HIPEC protocols were clinically and pharmacologically evaluated in a randomized phase III clinical pilot trial. Oxaliplatin dose was 460 mg/m 2 (BSA‐based) in 2 L/m 2 carrier solution (concentration‐based). Platinum quantification was performed using a validated inductively coupled plasma mass spectrometry method. Three‐month morbidity, mortality, and health‐related quality of life (HRQOL) were assessed.Results: Thirty‐one patients were randomized to either BSA‐ or concentration‐based HIPEC. Toxicity and efficacy were higher (P < 0.001) in patients receiving concentration‐based HIPEC. There was no difference in pharmacologic advantage between the two groups. A higher drug concentration in the tumor nodule at the end of HIPEC was found in the HIPEC‐concentration group. There was no difference in major morbidity and mortality between the treatment groups. HRQOL was decreased 3 months postoperatively in the HIPEC‐concentration group.Conclusion: Concentration‐based chemotherapy delivers the drug in the most standardized way to the tumor nodule, resulting in increasing drug concentrations in the tumor nodule without increasing major morbidity.Keywords
Funding Information
- Agentschap voor Innovatie door Wetenschap en Technologie (141631)
- Limburg Sterk Merk
This publication has 41 references indexed in Scilit:
- The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI)European Journal of Surgical Oncology, 2018
- A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7.Journal of Clinical Oncology, 2018
- Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesotheliomaInternational Journal of Hyperthermia, 2017
- Importance of standardizing the dose in hyperthermic intraperitoneal chemotherapy (HIPEC): a pharmacodynamic point of viewCancer Chemotherapy and Pharmacology, 2013
- Peritoneal surface area: measurements of 40 structures covered by peritoneum: correlation between total peritoneal surface area and the surface calculated by formulasSurgical and Radiologic Anatomy, 2009
- The transport barrier in intraperitoneal therapyAmerican Journal of Physiology-Renal Physiology, 2005
- Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal CancerJournal of Clinical Oncology, 2003
- Sex-dependent variations in peritoneal membrane transport properties in CAPD patientsNephrology Dialysis Transplantation, 1996
- Peritonectomy ProceduresAnnals of Surgery, 1995
- Measurements of Peritoneal Surface Area in Man and RatThe American Journal of the Medical Sciences, 1988